A carregar...
Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) who have an EGFR mutation. However, little has been reported about the association between EGFR exon 19 deletions or an exon 21 mutation (sp...
Na minha lista:
| Publicado no: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6636210/ https://ncbi.nlm.nih.gov/pubmed/31384460 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2019.1881 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|